Silvia Bungaro
About
In The Last Decade
Silvia Bungaro
12 papers receiving 317 citations
Peers
Comparison fields: 5 of 53
- Hematology 210
- Genetics 122
- Molecular Biology 91
- Rheumatology 74
- Public Health, Environmental and Occupational Health 74
Countries citing papers authored by Silvia Bungaro
This map shows the geographic impact of Silvia Bungaro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvia Bungaro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvia Bungaro more than expected).
Fields of papers citing papers by Silvia Bungaro
This network shows the impact of papers produced by Silvia Bungaro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvia Bungaro. The network helps show where Silvia Bungaro may publish in the future.
Co-authorship network of co-authors of Silvia Bungaro
This figure shows the co-authorship network connecting the top 25 collaborators of Silvia Bungaro. A scholar is included among the top collaborators of Silvia Bungaro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silvia Bungaro. Silvia Bungaro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 30 | |
| 3 | 0 | |
| 4 | 1 | |
| 5 | 12 | |
| 6 | 1 | |
| 7 | 4 | |
| 8 | 37 | |
| 9 | 43 | |
| 10 | Mechanisms of resistance to imatinib in chronic myeloid leukemia (CML) patients in chronic phase (CP) who achieved durable complete cytogenetic responses (CCR) | 1 |
| 11 | Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. | 182 |
| 12 | 24 | |
| 13 | STI571 administered to chronic myeloid leukemia (CML) patients inhibits cell proliferation, induces apoptosis and initially causes partial inhibition of BCR/ABL autophosphorylation | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.